Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

5G-EMERALD: A Phase 1 Trial of Amivantamab in High Grade Malignant Brain Tumours Within the 5G Platform

NCT06632236 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT06632236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06632236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
5G-EMERALD: A Phase 1 Trial of Amivantamab in High Grade Malignant Brain Tumours Within the 5G Platform
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 9, 2024
Completion date
July 1, 2027
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse hemispheric glioma, h3 g34-mutant, glioblastoma multiform (grade iv astrocytoma), glioblastoma multiforme (gbm), malignant primary gliomas